Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Nitto Denko, Alnylam, UMDNJ, and More

Premium

Title: Therapeutic Agent for Pulmonary Fibrosis

Patent Number: 8,574,623

Filed: Oct. 10, 2012

Lead Inventor: Yoshiro Niitsu, Nitto Denko

The patent claims a delivery carrier containing a retinoid-targeting agent designed to carry therapeutic agents to extracellular matrix-producing cells in the lung. It also claims the use of an siRNA targeting heat shock protein 47 to treat pulmonary fibrosis.


Title: Methods and Kits for miRNA Isolation and Quantitation

Patent Number: 8,574,838

Filed: July 14, 2011

Lead Inventor: Chunxiang Zhang, University of Medicine and Dentistry of New Jersey

The invention comprises "a kit and method for isolating and quantitating miRNA and the use of such methods in the diagnosis and prognosis of disease," according to the patent's abstract.


Title: Conserved HBV and HCV Sequences Useful for Gene Silencing

Patent Number: 8,575,327

Filed: Dec. 12, 2005

Lead Inventor: Catherine Pachuk, Nucleonics (Alnylam Pharmaceuticals)

The patent claims "conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells," according to its abstract. "These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans."


Title: Formicidae Control Using Double-stranded RNA Constructs

Patent Number: 8,575,328

Filed: Dec. 13, 2011

Lead Inventor: Robert Vander Meer, US Department of Agriculture

The invention, the patent's abstract states, comprises "a dsRNA construct that relates to a method to control Formicidae via double-stranded RNA interference of the PBAN/Pyrokinin gene."


Title: siRNA Targeting Kinase Insert Domain Receptor

Patent Number: 8,575,329

Filed: June 15, 2012

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR."


Title: microRNA-based Short Hairpin RNA for Gene Knockdown of NR1 Subunit N-methyl-D-aspartate Receptor and its Application on Pharmaceutics

Patent Number: 8,575,330

Filed: July 10, 2012

Inventor: Ping-Heng Tan, I-Shou University

The invention, the patent's abstract states, relates to a "microRNA-based short hairpin RNA for gene silencing the genetic expression of NR1 subunit of N-methyl-D-aspartate receptor."

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.